Research analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- The Average 401k Balance by Age Explained
- What is the Shanghai Stock Exchange Composite Index?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is a Special Dividend?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.